Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S; UK and Spanish Collaborative Groups.
Peggs KS, et al. Among authors: alvarez i.
Br J Haematol. 2007 Oct;139(1):70-80. doi: 10.1111/j.1365-2141.2007.06759.x.
Br J Haematol. 2007.
PMID: 17854309
Free article.
Clinical Trial.